In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of $45.00. The company’s shares closed yesterday ...

Shares in CureVac have plummeted after a German court ruled that a patent it holds on mRNA-based COVID-19 vaccines was invalid. The validity of the patent is at the heart of patent litigation ...

The trial compared Moderna's MRNA-4157/V940 vaccine given alongside Merck & Co's cancer immunotherapy Keytruda (pembrolizumab) to Keytruda alone in patients with the skin cancer melanoma.

Typically miRNAs interact with specific mRNAs through complementary base-pairing to influence the translation or stability of the target mRNA molecule. Acquired miR-142 deficit in leukemic stem ...

Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Creating a strong brand identity ...

Making the world smarter, happier, and richer.

After hours: January 31 at 7:59:52 p.m. EST ...

Real time quote data is not available at this time. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.